Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

R. Champlin*, I. Khouri, P. Anderlini, J. Gajewski, S. Kornblau, J. Molldrem, A. Shimoni, N. Ueno, S. Giralt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versus-malignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors.

Original languageEnglish
Pages (from-to)S13-S22
JournalBone Marrow Transplantation
StatePublished - May 2001
Externally publishedYes


  • Graft-versus-malignancy effect
  • Nonmyeloablative allogeneic transplantation


Dive into the research topics of 'Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation'. Together they form a unique fingerprint.

Cite this